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ABSTRACT 
Epigenetic mechanisms such as histone methylation are considered as one of the most important mediators that 
control stem cell behaviors such as proliferation, senescence and differentiation. G9a, a histone methyltransferase, 
has recently generated intense attention as potential target for controlling many diseases such as cancers. The aim 
of the present study was to evaluate the effect of in vivo administration of A366, a G9a inhibitor, on proliferative 
and differentiation potential of bone marrow-derived mesenchymal stem cells (BM-MSCs). We inhibited G9a 
using intraperitoneally administration of A366, and we evaluated BM-MSC proliferation and differentiation be-
haviors in vitro. Colony formation assay of BM-MSCs at primary culture showed that in vivo administration of 
A366 reduced the colony forming capacity of BM-MSCs. Moreover, PDT of BM-MSC isolated from A366-treated 
rats was higher than control, especially in the early passages. BM-MSC isolated from A366-treated rats showed 
higher adipogenic potential compared to the control at the early passages as determined by gene expression and 
Oil Red staining. Whereas, osteogenic potential of BM-MSC isolated from A366-treated rats was lower than con-
trol, especially at early passages. Our results suggest that the epigenetic modifier such as A366, which seems to 
be a therapeutic approach for controlling diseases such as cancer, might also influence the proliferation and dif-
ferentiation capacity of MSCs both in vitro and in vivo. Moreover, epigenetic modifying chemicals seem to be a 
strategy to manipulate MSC expansion capacity and differentiation propensity, as well as to efficiently involve-
ment of MSCs in tissue homeostasis, cell-based therapy and tissue engineering. 
 
Keywords: bone marrow-derived mesenchymal stem cells, histone methyltransferase G9a, adipogenesis, osteo-
genesis, A366 
 
 
 
INTRODUCTION 
Mesenchymal stem cells (MSCs) also 
called mesenchymal stromal cells are a heter-
ogeneous population of fibroblast-like cells of 
non-hematopoietic origin, which have been 
isolated from a variety of connective tissues 
such as bone marrow (Fitzsimmons et al., 
2018). MSCs easy isolation, simple culture, 
multiple isolation source, differentiation po-
tential and secretory and immunomodulatory 
capacity of MSCs, make these cells as golden 
choice for cell-based therapy, tissue engineer-
ing, pharmaceutical industry and other poten-
tial applications (Liubaviciute et al., 2018).  
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Today it is well-known that epigenetic 
mechanisms control the stem cell behaviors 
(e.g. secretion, differentiation and prolifera-
tion) during homeostasis, aging, and disease 
(Beerman and  Rossi 2015; Ghasemzadeh et 
al., 2018). Histone methylation is one of the 
epigenetic mechanisms that can strongly af-
fect stem cell behaviors by activating or re-
pressing gene expression. Histones methyla-
tions occur by several histone methyltransfer-
ases (HMTs) and methylations are dynami-
cally removed by histone demethylases 
(HDMs) (Cho et al., 2015). G9a, a HMT be-
longing to the Su(var)3-9 family, is responsi-
ble for histone H3 lysine 9 (H3K9) mono- and 
demethylation (H3K9me1/2) in vivo and in 
vitro (Casciello et al., 2015). It is important to 
note that G9a is overexpressed in a number of 
cancers, including esophageal squamous cell 
carcinoma, hepatocellular carcinoma, aggres-
sive lung cancer, brain cancer, multiple mye-
loma, and aggressive ovarian carcinoma 
(Casciello et al., 2015). Since these epigenetic 
modifications are reversible, HMTs can be a 
potential target for controlling cancers. In ad-
dition to the G9a roles in cancer, it has an im-
portant role at normal development and stem 
cells differentiation. Although different func-
tions have been reported for G9a during de-
velopment, stem cell differentiation and can-
cers (Casciello et al., 2015; Pappano et al., 
2015; Wang et al., 2013), but it isn’t under-
stood the effects of in vivo G9a inhibition, as 
a potential strategy for cancer treatment, on 
proliferation properties and differentiation 
potential of bone marrow-derived mesenchy-
mal stem cells (BM-MSCs) in vitro and in 
vivo. 
Here, we injected intraperitoneally a dose 
of 25 mg/kg A366 to wistar rats (a single 
time). Then, the clonogenicity, population 
doubling time, adipogenic and osteogenic dif-
ferentiation potential, and cell cycle were an-
alyzed for the BM-MSC isolated from A366-
treated and control rats. Our results showed 
that in vivo administration of A366 decreased 
proliferation capacity and increased adipo-
genic potential of BM-MSCs. While, osteo-
genesis was reduced following in vivo admin-
istration of A366. 
 
MATERIALS AND METHODS 
In vivo chemical treatment and cell culture 
To investigate the effects of in vivo ad-
ministration of A366 on proliferation and dif-
ferentiation potential of BM-MSCs, a single 
dose of 25 mg/kg of A366 (dissolved in 
DMSO and diluted with water) was injected 
intraperitoneally in rats (purchased from 
Royan Institute, Tehran, Iran). Control rats 
were given DMSO diluted with water. 2 days 
after IP injection, A366-treated rats and con-
trols were sacrificed and the bone marrow 
cells were isolated as we previously described 
(Baghaban Eslaminejad et al., 2008a). Animal 
protocols were approved by the Institutional 
Animal Care and Use Committee at Shahid 
Beheshti University (SBU). BM-MSCs were 
cultured with MSC medium (Dulbecco’s 
Modified Eagles Medium (Fisher Scientific) 
supplemented by 15 % Fetal Bovine Serum 
(Sigma Aldrich) and Penicillin-Streptomycin 
(Gibco) at 37 °C and 5 % CO2. The medium 
was changed with fresh medium every 2-3 
days. In the present study, different passages 
of BM-MSCs were used (mentioned in each 
experiment). Population doubling time, cell-
cycle profile and differentiation assay were 
analyzed for BM-MSCs isolated from treated 
and control rats. 
 
Confirming the identity of the cultured  
BM-MSCs  
Flow cytometry analysis (for surface 
markers CD90, CD73, and CD45) and differ-
entiation assays (adipogenesis, osteogenesis 
and chondrogenesis) were used to confirm the 
identity of isolated BM-MSCs. To analyze the 
surface markers, BM-MSCs (at P3) were 
stained with FITC- or PE-conjugated anti-rat 
antibodies (BD, Bioscience), or with their iso-
types, according the BD Bioscience protocol, 
then the cells were analyzed using a flow cy-
tometer (FACSCalibur; BD Biosciences) and 
flowing software, version 2.5.1 (BD Biosci-
ences). The MSC identity also was confirmed 
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by differentiation of MSCs (at P3) to adipo-
cyte, osteocyte and chondrocyte (Baghaban 
Eslaminejad et al., 2008b). Osteogenic, adi-
pogenic and chondrogenic differentiation 
were determined using Alizarin Red, Oil Red, 
and toluidine blue staining, respectively. 
 
Cell population doubling time (PDT) 
To determine the effect of in vivo admin-
istration of A366 on BM-MSC proliferation, 
105 BM-MSCs derived from A366-treated 
rats and controls, were seeded at each well of 
a 6-well plate. Cells were cultured for 4-6 
days, and their media were changed every 48 
hours, and PDT was calculated for the cells in 
each passage. PDT was examined using the 
formula:  
ሺt	 െ 	t0ሻ ∙ log2
logሺN	 െ 	N0ሻ  
where t − t0 is culture time (h), N is the num-
ber of harvested cells and N0 is the number of 
cells in the initial. 
 
Cell cycle analysis 
For analyzing cell cycle of BM-MSCs iso-
lated from A366-treated and control rats, 105 
BM-MSCs (P1-P3) were seeded at each well 
of a 6-well plate. After 2 days, the cells were 
trypsinized and harvested, then cells were 
prepared for cell cycle analysis, according to 
a standard protocol (Moradi et al., 2017). 
Flow cytometry was performed using a BD 
FACSCalibur (BD Biosciences) and the data 
were analyzed with BD FACSDiva (BD Bio-
sciences). 
 
Osteogenic differentiation  
Osteogenic differentiation was induced 
using osteogenic differentiation medium (reg-
ular MSC medium supplemented with 50 
mg/ml ascorbic 2-phosphate (Sigma-Al-
drich), 10 nM dexamethasone (Sigma-Al-
drich) and 10 mM ß-glycerol phosphate 
(Sigma-Aldrich) at P1-P3. Next, osteogenic 
differentiation was determined using Real-
time PCR (see below) and Alizarin Red on 
day 21 of differentiation. Images were cap-
tured using a digital camera system (Olympus 
DP72) connected to an inverted optical micro-
scope (Olympus CKX41-Olympus Optical 
CO). For quantitation the Alizarin Red stain-
ing, differentiated osteocytes were gently 
washed by PBS and fixed with 4 % paraform-
aldehyde in PBS (Sigma-Aldrich) for 15 min. 
Subsequently, the cells were washed with dis-
tilled water, exposed to Alizarin Red S 
(Sigma-Aldrich) for 20 min at room tempera-
ture, and washed again with distilled water for 
5 min for 4 times. For quantification of Aliz-
arin Red S staining, the dye was desorbed us-
ing 10 % (wt/vol) cetylpyridinium chloride 
(Sigma, C9002) for 1 hour and absorbance 
was determined at 540 nm using a Thermo 
Scientific™ Multiskan™ GO Microplate 
Spectrophotometer (Thermo Scientific™, 
USA). To analyze the ALP activity in osteo-
cytes, Alkaline Phosphatase Assay Kit 
(abcam; ab83369) was used. ALP activity 
was determined based on the manufacturer’s 
protocol and the results were measured at 405 
nm (Thermo Scientific™, USA). 
 
Adipogenic differentiation 
Adipogenic differentiation was induced 
using adipogenic differentiation medium 
(regular growth medium supplemented with 
50 mg/ml ascorbic 2-phosphate (Sigma-Al-
drich), 10 nM dexamethasone (Sigma-Al-
drich) and 10 mM ß-glycerol phosphate 
(Sigma-Aldrich) at P1 and P2. After 3 weeks, 
the adipogenesis was assessed using Real-
time PCR (see below) and Oil Red staining 
(Sigma Aldrich™). Images were captured us-
ing a digital camera system (Olympus DP72) 
connected to an inverted optical microscope 
(Olympus CKX41-Olympus Optical CO). 
 
Chondrogenic differentiation 
To induce chondrogenesis, micro mass 
culture system was used (Baghaban 
Eslaminejad et al., 2008b). Briefly, 2.5×105 
BM-MSCs (at P3) was pelleted using centri-
fuge and cultured for three weeks in chondro-
genic differentiation medium (DMEM sup-
plemented with 10 % ITS+ Premix (Sigma-
Aldrich), 10−7 M dexamethasone (Sigma-Al-
drich), 1 μM ascorbate-2-phosphate (Sigma-
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Aldrich), 1 % sodium pyruvate (Sigma-Al-
drich), 10 ng/ml BMP6 (Sigma-Aldrich) and 
10 ng/ml transforming growth factor-beta 1 
(TGF-β1, Sigma-Aldrich). At the end of dif-
ferentiation, the chondrogenic aggregates 
were sectioned and stained using toluidine 
Blue, and viewed by light microscope.  
 
RNA isolation and real-time PCR 
To analyze the expression of osteogenic 
and adipogenic specific markers, MSCs were 
cultured for three weeks in osteocyte and adi-
pocyte inducing medium, respectively. Then 
the cells were collected, RNAs were ex-
tracted, cDNA were synthesized and real-time 
PCR was performed using a standard proce-
dure that we previously described (Talkhabi 
et al., 2015). GAPDH was used as the internal 
control to normalize the expression of genes 
of interest. The results were presented as rel-
ative fold change compared to the control. 
The statistical significance was calculated by 
Student’s t-test, and P values <0.05 were con-
sidered significant. The primer sequences for 
osteogenic and adipogenic genes and 
GAPDH are listed in Table 1. 
 
RESULTS 
Characteristics of BM-MSCs 
The BM-MSCs isolated from A-366 
treated rats and controls were expanded and 
cultured as plastic-adherent cells with a typi-
cal fibroblastic-like shape (Figure 1). The 
BM-MSCs isolated from A-366 treated rats 
and controls had capacity to differentiate into 
three important lineages including osteocytes, 
adipocytes and chondrocytes (Figure 1). 
Since BM-MSCs don’t have any single spe-
cific marker determining their identity, so 
three known CD markers were analyzed for 
BM-MSCs. As expected, the majority of BM-
MSCs were positive for CD90, CD73 
(≃90 %), while most of the cells (≥ 98 %) 
were negative for CD45 (Figure 1). These 
three assessment confirmed that the isolated 
and investigated cells had MSC identity.  
 
Table 1: The list of primers used for real-time PCR 
  
 
Figure 1: Characterization of BM-MSCs. BM-MSCs were isolated from A366-treated and control rats 
were assessed at P3. BM-MSCs isolated from both groups grew up as adherent cells with fibroblastic 
morphology. They had potential to differentiate to osteocytes, chondrocytes and adipocytes as deter-
mined by Alizarin Red, Toluidine Blue and Oil Red staining, respectively. They also were positive for 
CD73, CD90, and negative for the hematopoietic markers CD45.
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In vivo inhibition of G9a decreased clono-
genicity and proliferation rate of BM-MSCs 
To analyze the clonogenicity of BM-MSC 
isolated from A366 treated rats and controls, 
the number of MSC colonies formed at pri-
mary culture were counted after Giemsa stain-
ing (Figure 2A). We found that the number of 
colonies formed in the bone marrow cells iso-
lated from A366-treated rats were signifi-
cantly lower compared to the control (Figure 
2B). To investigate whether inhibitory effect 
of A366 on BM-MSC clonogenicity can sus-
tain during BM-MSC culture and expansion, 
we analyzed the colony forming capacity of 
BM-MSCs at the next passages. We found 
that at P1, the number of colonies formed by 
BM-MSC isolated from A366-treated rats 
was lower compared to the control (Figure 
2B). Whereas, the difference between the 
number of colonies at P1 was not significant. 
There was also no significant difference be-
tween the number of colonies formed by BM-
MSCs that were isolated from A366-treated 
rats and controls at P2 (Figure 2B) and P3 
(n=2, data not shown). We also determined 
the PDT for BM-MSC isolated from A366-
treated rats and controls at P1-P3. It was real-
ized that at P1, the PDT of BM-MSC isolated 
from A366-treated rats was ~40 hours, which 
was approximately 13 hours longer than PDT 
of the control. Whereas, there was almost no 
difference in PDT of BM-MSCs at P2 and P3 
(Figure 2C). Next, we analyzed the effect of 
in vivo administration of A366 on cell cycle 
profile. Therefore, cell cycle analysis of BM-
MSC isolated from A366-treated rats and 
controls was calculated at primary culture and 
P1-P3.  
 
 
 
Figure 2: Effects of 
in vivo administra-
tion of A366 on 
clonogenicity and 
proliferative capac-
ity of BM-MSCs. 
(A) Microscopic 
morphology of BM-
MSCs at primary 
culture and P1. 
A366 decreased 
the clonogenicity of 
BM-MSCs at early 
passages; each 
black dotted circle 
is a colony of BM-
MSC. Inset shows 
two colonies after 
Giemsa staining, 
(B) BM-MSC iso-
lated from A366-
treated rats formed 
significantly fewer 
colonies at primary 
culture in vitro, (C) 
BM-MSC isolated 
from A366-treated 
rats had signifi-
cantly longer PDT 
than those isolated 
from control rats at the early passage, (D) cell cycle profile of BM-MSC; the proportion of cells at Sub-
G1/G0 stage was larger in BM-MSC isolated from A366-treated rats than control, only at the primary 
culture. a': P < 0.05 vs a. Data are expressed as means ± SD. 
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We found that in the primary culture, the 
proportion of cells at Sub G1/G0 stage was 
higher in BM-MSC isolated from A366-
treated rats than control (Figure 2D). 
Whereas, the proportion of cells at G2 and S 
was lower in BM-MSC isolated from A366-
treated rats than control (Figure 2D). Interest-
ingly, the proportions of cells at Sub G1/G0, 
G1, S and G2/M were not significantly differ-
ent between BM-MSC isolated from A366-
treated rats and control at P1-P3. 
 
In vivo inhibition of G9a increased  
adipogenesis of BM-MSCs 
Microscopic analysis showed that BM-
MSC isolated from A366-treated rats had a 
higher potential to differentiate into lipid 
droplet containing adipocytes at the first pas-
sage (Figure 3A, top). However, there was ap-
proximately no difference between adipo-
genic differentiation of BM-MSC isolated 
from A366-treated rats and controls at P2 
(Figure 3A, top) and P3 (data not shown). 
Consistent with microscopic observations, 
Oil Red staining of adipocyte differentiated 
from BM-MSCs at P1 revealed that in vivo 
administration of A366 increased the adipo-
genic potential of BM-MSCs in vitro (Figure 
3A, bottom). We next analyzed the expression 
of adipocyte specific genes including peroxi-
some proliferator activated receptor gamma 
(PPAR-γ2), lipoprotein lipase (LPL) and 
CCAAT Enhancer Binding Protein Alpha 
(C/EBPα) in adipocytes differentiated from 
BM-MSC. We found that the expression of 
adipocyte specific genes was significantly 
higher in adipocytes differentiated from BM-
MSC isolated from A366-treated rats than 
controls (Figure 3B). 
 
 
Figure 3: The effects of in vivo administration of 
A366 on adipogenic potential of BM-MSCs. (A) 
Most of BM-MSCs were differentiated to lipid 
droplet containing adipocytes in P1/BM-MSC iso-
lated from A366 treated rats. BM-MSC isolated 
from A366-treated rats and control had same po-
tential to generate adipocytes at P2 (Top). Oil red 
staining of the adipocytes differentiated from BM-
MSC isolated from A366 treated and untreated 
rats (Bottom), (B) Gene expression analysis of 
BM-MSC-derived adipocytes. PPAR-γ2: peroxi-
some proliferator activated receptor gamma, LPL: 
lipoprotein lipase, C/EBPα: CCAAT Enhancer 
Binding Protein Alpha 
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In vivo inhibition of G9a decreased  
osteogenesis of BM-MSCs 
Osteogenesis assessment using Alizarin 
Red staining showed that the osteogenic dif-
ferentiation in P1/BM-MSCs isolated from 
A366-treated rats severely decreased com-
pared to the osteogenic differentiation of con-
trol isolated BM-MSCs. Accordingly, the 
P1/BM-MSCs isolated from A366-treated 
rats produced fewer osteocyte-like cells com-
pared to the control (Figure 4A). Interest-
ingly, the percentage of osteocytes was al-
most similar in P2/BM-MSC isolated from 
A366-treated rats and controls (Figure 4A). 
Quantitative analysis of mineralization con-
firmed the microscopic observation of Aliza-
rin Red stained osteocytes. Colorimetric 
quantification showed that the amount of min-
eralized extracellular matrix was significantly 
lower in osteocytes differentiated from 
P1/BM-MSCs that were isolated from A366-
treated rats compared to the control (Figure 
4B, left). Although, there was approximately 
no difference in the amount of mineralized 
matrix of osteocytes differentiated from 
P2/BM-MSCs of both groups (Figure 4B, 
left). Consistence with Alizarin Red staining 
results, ALP activity was significantly lower 
in osteocytes differentiated from P1/BM-
MSCs isolated from A366-treated rats (Figure 
4B, right). The level of ALP activity in osteo-
cytes derived from A366-treated rats P2/BM-
MSCs, increased to the control level. We also 
analyzed the expression of osteogenesis spe-
cific genes in osteocytes generated from 
P1/BM-MSCs of both groups (Figure 4C). 
The relative expression of osteogenesis spe-
cific genes including Runt-related transcrip-
tion factor 2 (Runx2), Osteocalcin (OCN), al-
kaline phosphatase (ALP), zinc finger protein 
Osterix (OSX) and Collagen Type I Alpha 1 
Chain (Col1a1) was significantly higher in os-
teocytes derived from control BM-MSCs 
(Figure 4C). 
 
 
Figure 4: The effects of in vivo administration of 
A366 on osteogenic potential of BM-MSCs. (A) 
Alizarin red staining of BM-MSC-derived osteo-
cytes. The osteogenic potential of the BM-MSC 
isolated from A366-treated rats clearly is lower 
than control at P1, whereas it is almost similar at 
P2; (B, left) Absorbance-based quantification of 
Alizarin Red staining showed that in vivo admin-
istration of A366 reduced the amount of extracel-
lular matrix deposition by osteocytes differenti-
ated from P1/BM-MSCs; (B, right) ALP activity 
was significantly lower in osteocytes differentiated 
from P1/BM-MSC that were isolated from A366-
treated rats; (C) the gene expression analysis of 
osteocytes differentiated from BM-MSCs. a': P < 
0.05 vs a. Data are expressed as means ± SD. 
Runx2: Runt-related transcription factor 2, OCN: 
Osteocalcin, ALP: alkaline phosphatase, OSX: 
Osterix and Col1a1: Collagen Type I Alpha 1 
Chain 
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DISCUSSION 
Here, we used A366 to inhibit histone ly-
sine methyltransferase G9a (EHMT2), which 
is an epigenetic regulator that modify key ly-
sine and arginine residues on histones, 
thereby plays an important role in cancer de-
velopment and maintenance. The effects of in 
vivo administrated G9a inhibitors on BM-
MSC biological behaviors have not been in-
vestigated. It is known that anticancer chemi-
cals might strongly affect other normal cells, 
especially MSCs that play important roles in 
many tissues. Therefore, we used A366 both 
in vitro (unpublished data) and in vivo, and 
analyzed the biological behaviors of BM-
MSCs. It has been reported that A366 has sig-
nificantly less cytotoxic effects compared to 
other known G9a/GLP inhibitors such as 
BIX01294, despite equivalent cellular activ-
ity on methylation of H3K9me2 (Pappano et 
al., 2015). We found that in vivo administra-
tion of A366 heavily affected the proliferation 
and differentiation of BM-MSCs. We found 
that A366 decreased the colony-forming ca-
pacity of MSCs in primary culture, while col-
ony-forming capacity of A366-treated and 
control were similar at the next passages, sug-
gesting that the antiproliferative effect of 
A366 cannot sustain during in vitro expansion 
of BM-MSCs. However, it is not clear the 
mechanism thereby A366 decreased the num-
ber or capacity of colony-forming MSCs. 
Similar results were obtained from PDT as-
say. Accordingly, in vivo administration of 
A366 significantly prolonged PDT in the first 
passage, whereas PDT for BM-MSCs isolated 
from A366-treated rats and controls was ap-
proximately similar in the next passages, sug-
gesting A366 effect was erased during in vitro 
expansion. The anti-proliferation effects of 
G9a inhibition have been reported for other 
cell types such as Leukemia cell lines 
(Pappano et al., 2015). We also found that in 
vivo administration of A366 had a noticeable 
effect on differentiation potential of BM-
MSCs. A366 increased and decreased the ad-
ipogenic and osteogenic potential of BM-
MSCs, respectively. However, these effects 
were observed only in the first passages, sug-
gesting that the effects of A366 cannot sustain 
during in vitro expansion. The findings of the 
present study are supported by previous re-
ports indicated that H3K9me2 and G9a levels 
decrease during adipogenesis, which corre-
lates inversely with induction of PPARγ 
(Wang et al., 2013). It has been shown that 
G9a inhibition enhances PPARγ and C/EBPα 
expression and adipogenesis in preadipo-
cytes, whereas forced expression of G9a im-
pairs the accumulation of triglycerides (Li et 
al., 2013). It seems that in vivo inhibition of 
G9a using A366 or other chemicals might 
also increase the weight of adipose tissue, and 
enhance the propensity of tissue specific 
MSCs to differentiate into adipocytes.   
We also found that G9a inhibition de-
creased the propensity of BM-MSCs to differ-
entiate to osteocyte, suggesting that G9a inhi-
bition might disturb the establishment of the 
gene regulatory network required for osteo-
genesis initiation. It has been reported that 
G9a interacts with Runx2 and promotes the 
transcriptional activation of Runx24 (Purcell 
et al., 2012). In consistent with our findings, 
it has been reported that the expression of G9a 
is increased in osteoblasts and during prehy-
pertrophic and hypertrophic chondrocyte for-
mation at E16.5 (Ideno et al., 2013). There-
fore, inhibition of G9a using A366 or other 
chemicals might impair MSC involvement in 
tissue repair such as bone formation and re-
modeling.  
Interestingly, G9a inhibition has different 
effects on other differentiation potentials of 
mesenchymal cells/MSCs in vivo and in vitro. 
Like the inhibitory role of G9a in osteogene-
sis, it also works as negative regulator for my-
ogenic differentiation. Yang and colleagues 
showed that inhibition of G9a by gene spe-
cific knockdown or BIX01294 treatment in-
duced the expression of cardiogenesis spe-
cific markers such as Mesp1 and brachyury in 
bone marrow cells (Mezentseva et al., 2012; 
Yang et al., 2015). Moreover, G9a works as 
positive regulator during neurogenesis from 
MSCs. Kim and colleagues showed that G9a 
inhibitor BIX01294 increased expression of 
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various neuronal-lineage genes in human 
MSCs (Kim et al., 2016). 
Taken together, inhibition of G9a using 
A366 or other chemicals might impair MSC 
involvement in tissue repair such as bone for-
mation and remodeling. Although, G9a inhi-
bition using A366 or other chemicals and ap-
proaches seems to be a strategy to control can-
cers, it might have unexpected and cata-
strophic effects on behaviors of MSCs found 
in several organs and tissues in the body. It 
will also be interesting to analyze the effects 
of in vivo administration of A366 on biologi-
cal behaviors of other stem cells, as well as on 
MSC potential for differentiation into other 
lineages such as myocyte or neural cells. 
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